⏱ News is delayed by 15 minutes. Sign in for real-time access.
Sign in
IRD News
Opus Genetics, Inc. Common Stock
Opus Genetics Provides BEST1 Program Update with Detailed Timeline for OPGx-BEST1 Results
globenewswire.com
IRD
Opus Genetics Announces FDA Alignment on Phase 3 Registrational Trial Design for OPGx-LCA5 in LCA5-Associated Inherited Retinal Disease
globenewswire.com
IRD
Opus Genetics Added to the Russell 3000®, Russell 2000® and Russell Microcap® Indexes
globenewswire.com
IRD
Form 8-K
sec.gov
IRD
Opus Genetics Highlights Five Gene Therapy Programs Targeting Significant Unmet Need in Patients with Inherited Retinal Diseases
globenewswire.com
IRD
Form 8-K
sec.gov
IRD
Opus Genetics to Host Virtual R&D Science Forum on Tuesday, June 16, 2026 Featuring Multiple Inherited Retinal Disease Experts
globenewswire.com
IRD
Opus Genetics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
globenewswire.com
IRD
Opus Genetics to Present at the 2026 Jefferies Global Healthcare Conference
globenewswire.com
IRD
Opus Genetics to Present at the RBC Capital Markets 2026 Global Healthcare Conference
globenewswire.com
IRD